Glucagon-like peptide-1 cleavage product GLP-1(9–36) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes-Reference-Cited by-同舟云学术

Glucagon-like peptide-1 cleavage product GLP-1(9–36) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes

Published:2020-11 Issue: Volume:887 Page:173581
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Huang Jing,Liu Yunhan,Cheng Liusiyuan,Li Jihong,Zhang Tangrui,Zhao Gang,Zhang Huinan

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference51 articles.

1. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade;Aulinger;Diabetes,2014

2. Biology of incretins: GLP-1 and GIP;Baggio;Gastroenterology,2007

3. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor;Ban;Endocrinology,2010

4. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways;Ban;Circulation,2008

5. Astrocytes: targets for neuroprotection in stroke;Barreto;Cent. Nerv. Syst. Agents Med. Chem.,2011

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9-36) in conjunction with LSN3318839;Acta Pharmaceutica Sinica B;2024-09

2. Astrocyte modulation in cerebral ischemia-reperfusion injury: A promising therapeutic strategy;Experimental Neurology;2024-08

3. Chronic exposure to incretin metabolites GLP-1(9−36) and GIP(3−42) affect islet morphology and beta cell health in high fat fed mice;Peptides;2024-08

4. Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9-36) in conjunction with LSN3318839;2024-07-22

5. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide;Cardiovascular Diabetology;2024-07-10